Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Stock Short Interest Rises 715.0%

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 271,866 shares, an increase of 715.0% from the August 31st total of 33,356 shares. Currently, 26.5% of the company’s shares are sold short. Based on an average daily volume of 20,006,870 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

An institutional investor recently bought a new stake in Biodexa Pharmaceuticals stock. Sabby Management LLC acquired a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals accounts for approximately 0.6% of Sabby Management LLC’s portfolio, making the stock its 10th biggest holding. Sabby Management LLC owned approximately 28.04% of Biodexa Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Stock Performance

BDRX stock traded up $0.00 during midday trading on Friday, hitting $0.68. The company had a trading volume of 163,096 shares, compared to its average volume of 10,584,390. Biodexa Pharmaceuticals has a 52 week low of $0.61 and a 52 week high of $59.40. The stock’s 50 day moving average price is $1.20 and its 200 day moving average price is $2.60.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, September 14th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company combines drug candidates with proprietary delivery technologies intended to improve how therapies are administered, distributed, or released in the body.

Biodexa’s pipeline has included MTX110, a liquid formulation of the cancer medicine panobinostat being investigated for direct administration into brain tumors, including diffuse midline glioma.